Horizon Discovery has announced its partnership with the Human Protein Atlas, which will see the incorporation of Horizon’s CRISPR-edited knockout cell models into the Cell Atlas program.
In a Dec. 3, 2019 press release, Horizon Discovery has announced its partnership with the Human Protein Atlas, which will see the incorporation of Horizon’s CRISPR-edited knockout cell models into the Cell Atlas program.
Through the integration of the knockout cell models into the Cell Atlas program, it is hoped that understanding of genetic drivers of disease will be advanced. Additionally, knockout cell models offer a possibility of enhanced validation of antibodies based on genetic strategies as a result of the absence of the targeting protein, which correlates with a loss of signal for specific antibodies.
“Horizon has over a decade of experience in gene editing, and a well-established reputation for providing CRISPR-edited knockout cell models,” said Professor Emma Lundberg, who is responsible for the HPA Cell Atlas program, in the press release. “We have previously used Horizon’s cell lines in our high throughput imaging processes with great success. Using a validated gene-edited cell line where all cell models have the same background will be key to maximizing efficiency and achieving data reproducibility.”
Terry Pizzie, CEO, Horizon Discovery, added, “Having contributed to several thousands of publications in the field of human biology and disease, the HPA is a highly regarded knowledge provider and an expert in the field of molecular mechanisms of the human cell. We are delighted to partner with HPA to provide the robust research tools required to extend their database, and we are proud to be contributing to the expansion of this renowned open access resource for both academia and industry.”
Source: Horizon
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.